Skip to Main Content

Advertisement

Skip Nav Destination

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

Blood (2003) 101 (9): 3413–3415.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement